These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1987947)

  • 1. Multiple-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927.
    Lippa EA; Aasved H; Airaksinen PJ; Alm A; Bertelsen T; Calissendorff B; Dithmer O; Eriksson LO; Gustad L; Høvding G
    Arch Ophthalmol; 1991 Jan; 109(1):46-9. PubMed ID: 1987947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
    Bron A; Lippa EA; Gunning F; Bénichou C; Lesure P; Sirbat D; Royer J; Flament J; Clineschmidt C; Panebianco D
    Arch Ophthalmol; 1991 Jan; 109(1):50-3. PubMed ID: 1987948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
    Lippa EA; Carlson LE; Ehinger B; Eriksson LO; Finnström K; Holmin C; Nilsson SE; Nyman K; Raitta C; Ringvold A
    Arch Ophthalmol; 1992 Apr; 110(4):495-9. PubMed ID: 1562255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MK-927: a topically effective carbonic anhydrase inhibitor in patients.
    Bron AM; Lippa EA; Hofmann HM; Feicht BI; Royer JG; Brunner-Ferber FL; Panebianco DL; Von Denffer HA
    Arch Ophthalmol; 1989 Aug; 107(8):1143-6. PubMed ID: 2667509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients.
    Pfeiffer N; Hennekes R; Lippa EA; Grehn F; Garus H; Brunner-Ferber FL
    Br J Ophthalmol; 1990 Jul; 74(7):405-8. PubMed ID: 2198931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.
    Lippa EA; Schuman JS; Higginbotham EJ; Kass MA; Weinreb RN; Skuta GL; Epstein DL; Shaw B; Holder DJ; Deasy DA
    Ophthalmology; 1991 Mar; 98(3):308-12; discussion 312-3. PubMed ID: 2023750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE; Ghosh K; Gieser DK; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
    Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
    Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.
    Strahlman E; Tipping R; Vogel R
    Arch Ophthalmol; 1995 Aug; 113(8):1009-16. PubMed ID: 7639651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
    Higginbotham EJ; Kass MA; Lippa EA; Batenhorst RL; Panebianco DL; Wilensky JT
    Arch Ophthalmol; 1990 Jan; 108(1):65-8. PubMed ID: 2404488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Michaud JE; Friren B;
    Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A topical carbonic anhydrase inhibitor finally arrives.
    Palmberg P
    Arch Ophthalmol; 1995 Aug; 113(8):985-6. PubMed ID: 7639673
    [No Abstract]   [Full Text] [Related]  

  • 13. Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study.
    Gunning FP; Greve EL; Bron AM; Bosc JM; Royer JG; George JL; Lesure P; Sirbat D
    Graefes Arch Clin Exp Ophthalmol; 1993 Jul; 231(7):384-8. PubMed ID: 8406063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sezolamide: additivity to timolol twice daily.
    Gunning F; Béchetoille A; Lippa EA; Pfeiffer N; Gerling J; Holder D; Clineschmidt C; Buntinx A; Brunner-Ferber FL; Grehn F
    Eye (Lond); 1992; 6 ( Pt 5)():525-9. PubMed ID: 1286720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
    March WF; Ochsner KI
    Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical trial of MK-507, Trusopt, for raised intraocular pressure--the Australian experience.
    Gillies WE; Brooks AM
    Aust N Z J Ophthalmol; 1996 May; 24(2):111-5. PubMed ID: 9199740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Additive effect of timolol and the local carbonic anhydrase inhibitor MK-417 (sezolamide)].
    Pfeiffer N; Greve E; Béchetoille A; Lippa EA; Jaquet-Müller F; Gunning F; Gerling J; Grehn F
    Fortschr Ophthalmol; 1991; 88(6):846-7. PubMed ID: 1794818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Silver LH
    Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine].
    Pfeiffer N; Grehn F; Hennekes R; Garus H
    Fortschr Ophthalmol; 1990; 87(2):128-30. PubMed ID: 2192972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MK-927, a topical carbonic anhydrase inhibitor. Dose response and reproducibility.
    Serle JB; Lustgarten JS; Lippa EA; Camras CB; Panebianco DL; Podos SM
    Arch Ophthalmol; 1990 Jun; 108(6):838-41. PubMed ID: 2190547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.